Anti-CMV (UL97 inhibitor)
Maribavir
Brand names: Livtencity
Adult dose
Dose: 400mg PO BD for 8 weeks
Route: PO
Frequency: BD
Clinical pearls
- Refractory or resistant CMV post-transplant
- Specialist transplant ID
Contraindications
- Concurrent ganciclovir/valganciclovir (antagonism)
Side effects
- Dysgeusia
- Nausea
- Diarrhoea
- Fatigue
- Vomiting
- Tacrolimus level rise
Interactions
- Tacrolimus/ciclosporin/sirolimus (raised levels — monitor)
- Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine)
Monitoring
- CMV PCR
- Immunosuppressant trough levels
Reference: BNF; NICE TA860; SmPC; https://bnf.nice.org.uk/drugs/maribavir/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023